comparing different dosing schedules of oral isotretinoin for treatment of acne in 45 participants

Comparative therapeutic efficacy of different dosage regimens of oral isotretinoin in acne vulgaris - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094075

Enrollment

Registered

2025-09-01

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

Intervention1: dose of 20mg daily: All patients will receive oral isotretinoin in the dosage of 0.5mg/kg to a maximum of 20 mg as per allocation to the study groups for a fixed period of 12 weeks. The

Eligibility

Inclusion criteria

Inclusion criteria: All consecutive patients of acne vulgaris (Grade 2 and above) involving the face who have not received any treatment in the past four weeks.

Exclusion criteria

Exclusion criteria: 1. Pregnant females / females planning pregnancy within the next 9 months / breastfeedingfemales. 2. Immunosuppressed individuals. 3. Known hypersensitivity to synthetic / natural vitamin A. 4. Any systemic illness lasting more than three weeks. 5. Deranged liver function tests / lipid profile. 6. Reproductive age group females not willing to practice methods of contraception as advised.

Design outcomes

Primary

Measure	Time frame
To compare the percentage reduction in total acne lesion count at 12 weeks among the three treatment groups.Timepoint: 0,4,8,12 weeks	—

Secondary

Measure	Time frame
To compare the adverse effects associated with each dosage regimen of oral isotretinoin.Timepoint: 0,4,8,12 weeks	—

Countries

India

Contacts

Public ContactDr Priya Dagar

Government Medical College and Hospital

thamigp@yahoo.com9646121544

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026